SCHEMBL30004335

SCHEMBL30004335

Cc1c(F)cc(I)cc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAP2K1 Q02750 6/20 0.40
MAP2K2 P36507 2/20 0.40
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
NOTUM Q6P988 2/20 0.37
ASPH Q12797 1/20 0.36
KDM8 Q8N371 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
PTPRC P08575 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPRA P18433 1/20 0.36
PTPRB P23467 1/20 0.36
PTPRE P23469 1/20 0.36
PTPN6 P29350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26088361 1.00 KDM4E (0.41) KDM4EMEN1KMT2ATDP1MAP2K1
SCHEMBL22804436 0.79 SOS1 (0.41) KDM4ETDP1HDAC1HDAC6MYC
SCHEMBL31125282 0.79 SOS1 (0.41) KDM4ETDP1HDAC1HDAC6MYC
SCHEMBL1044811 0.79 MAP2K1 (0.45) KDM4EMAP2K1MAP2K2ASPHKDM8
SCHEMBL16652911 0.79 KDM4E (0.44) KDM4EMEN1KMT2ATDP1NOTUM
SCHEMBL5857864 0.79 CES2 (0.48) KDM4EMEN1KMT2ATDP1HDAC1
SCHEMBL29657075 0.79 CES2 (0.48) KDM4EMEN1KMT2ATDP1HDAC1
SCHEMBL27898301 0.78 HDAC1 (0.47) KDM4EMEN1KMT2ATDP1HDAC1
SCHEMBL16122323 0.76 PTPRC (0.41) KDM4EMAP2K1MAP2K2ASPHKDM8
SCHEMBL23090022 0.76 TDP1 (0.41) KDM4EMEN1KMT2ATDP1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852145-A GSPT1 degradation agent and application thereof 南京圣和药业股份有限公司 2024-10-29 CN disclosed
EP-4323350-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2024-02-21 EP disclosed
WO-2023069720-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
WO-2022219407-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-10-20 WO disclosed